UK Pom to P switch for Bayer's naproxen

Following the "prescription-only medicine" to "pharmacy" switch of Bayer Healthcare's naproxen 250 mg (April 01), a drug used in the treatment of primary dysmenorrhoea, the Royal Pharmaceutical Society of Great Britain has reaffirmed it's position that POM to P switches of this type are good for both the public and the pharmacy profession.

Sadia Khan, the RPAGB's lead pharmacist for self care, said: "the Society welcomes the reclassification of naproxen 250mg tablets and believes that this switch will provide women with more choice, convenience and better access to medicines for relief from period pain. It also enables pharmacists to use their skills and expertise in medicines. Details of alternative over-the-counter therapy choices for relief of pain and cramps associated with period pain are cited in the British National Formulary."